Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET

Company Participants

Alex Lobo - Stern Investor Relations

Milton Werner - Chief Executive Officer

Joseph Frattaroli - Chief Financial Officer

Conference Call Participants

Operator

Greetings, welcome to Inhibikase Therapeutics’ First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.

I will now turn the conference over to Alex Lobo, Stern Investor Relations. Thank you. You may now begin.

Alex Lobo

Thank you, Sherry. Good morning and welcome to Inhibikase Therapeutics first quarter 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. Yesterday afternoon Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2022. We encourage everyone to read yesterday's press release as well as Inhibikase’s quarterly report on Form 10-Q for the first quarter 2022, which is being filed with the SEC.

The company's press release and quarterly report are also available on Inhibikase’s website at inhibikase.com. In addition, this conference call is being webcast through the investor relations section of the company's website, and will be archived there for future reference.

Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time sensitive information that is accurate only as of the date of this live broadcast, May 17, 2022.

Actual results could differ materially from those stated or implied by these forward looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov.

The company undertakes no obligation to revise or update any forward looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.

With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you pay proceed.

Milton Werner

Thanks. And thank you, Alex, and thank you for everyone to joining Inhibikase Therapeutics’ first quarter 2022 earnings call. As we kicked off the year, we have worked diligently to advance our clinical and preclinical development programs as well as extend our thought leadership in Parkinson's disease. This past month, for example, we brought together leading KOLs in the field of movement disorders to host an educational investor event. We also participated in multiple medical conferences this past quarter, including the Annual AD/PD Conference where we presented results from our Phase 1 and Phase 1b studies for IkT-148009 as well as the Next Generation Kinase Inhibitors Summit, where we highlighted the rationale behind targeting c-Abl Parkinson's disease.